Aibotics, Inc. has transitioned through corporate reorganizations to focus on AI-powered robotics and support for psychedelic-based mental health treatments. Its acquisition of intellectual property such as the Phill Robot massage device and strategic partnerships underpin its early-stage product portfolio. Despite nominal revenue of $2,183 in fiscal year 2025, the company reported significant operating losses exceeding $1.8 million and net losses over $2.2 million, alongside a strained liquidity position with a current ratio near 0.06 [F1]. Regulatory requirements for clinical trials and controlled substances pose ongoing challenges. Key upcoming milestones include progress in clinical trial phases, pilot deployments of AI wellness devices, and integration of neurological data capture technologies [S1][S4][S8][S9][S10][F1].